Clinical Study
Role of Digoxin-Like Immunoreactive Substance in the Pathogenesis of Transient Tachypnea of Newborn
Table 3
Evaluation of hemodynamic and echocardiogram parameter on the 1st and 7th days of TTN and control groups.
| | Parameter* | TTN () | Control () | | | 1st daya | 7th dayb | 1st dayc | 7th dayd | a versus b | c versus d | a versus c | b versus d |
| | CO (mL/minute) |
(256–398) |
(277–345) |
(245–345) |
(256–334) | <0.01 | >0.05 | <0.05 | >0.05 | | EF (%) |
(48–55) |
(47–53) |
(47–55) |
(43–54) | <0.01 | <0.05 | <0.05 | >0.05 | | LVEDD (mm/kg) |
(28.0–33.2) |
(27.6–31.2) |
(28.0–33.0) | 2
(28.4–31.8) | <0.01 | >0.05 | <0.05 | >0.05 | | LVESD (mm/kg) |
(12.9–17.6) |
(10.7–14.5) |
(10.7–13.1) |
(10.5–12.8) | <0.001 | >0.05 | <0.001 | <0.01 | | RVEDD (mm/kg) |
(21.2–27.5) |
(19.5–27.4) |
(18.8–24.5) |
(18.7–24.2) | <0.05 | >0.05 | <0.01 | <0.01 | | RVESD (mm/kg) |
(10.2–13.0) |
(8.5–11.3) |
(8.0–12.1) |
(8.0–12.0) | <0.05 | >0.05 | <0.05 | >0.05 | | LA/Aorta |
(1.21–1.68) |
(0.99–1.26) |
(1.0–1.30) |
(1.0–1.30) | <0.001 | >0.05 | <0.001 | >0.05 | | FS (%) |
(27.0–34.0) |
(27.0–35.0) | 3
(28.0–35.0) |
(28.0–34.0) | >0.05 | >0.05 | >0.05 | >0.05 | | HR (/minute) |
(148–172) |
(133–165) |
(118–156) |
(110–153) | <0.001 | >0.05 | <0.001 | >0.05 | | mBP (mmHg) |
(44–65) |
(40–64) |
(40–57) |
(41–59) | >0.05 | >0.05 | <0.01 | >0.05 |
|
|
Values are represented as mean ± SD (min.–max.).
|
